CLINICAL EXPERIENCE WITH FIRST-LINE VRD IN PATIENTS DIAGNOSED WITH MULTIPLE MYELOMA

被引：0
|
作者：
De Miguel, Llorente Dunia [1 ]
Gil, Perez Angela [1 ]
Merchan, Munoz Beatriz [1 ]
Nuevo, Lopez Irene [1 ]
Perez, Ortega Alba [1 ]
Guillen, Garcia Helga [1 ]
Vazquez, Ramo Alejandro [1 ]
Subira, Perez Dolores [1 ]
Golbano, Lopez Nuria [1 ]
Santos, Montero Ana Belen [1 ]
Morales, Sanz Dolores [1 ]
Arbeteta, Juanis Jaime [1 ]
机构：
[1] Hosp Univ Guadalajara, Guadalajara, Spain
来源：
HAEMATOLOGICA | 2020年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO-026
引用
收藏
页码：150 / 151
页数：2
相关论文
共 50 条
  • [41] Postrelapse survival rate correlates with first-line treatment strategy with thalidomide in patients with newly diagnosed multiple myeloma: a meta-analysis
    Wang, Lida
    Cui, Jingying
    Liu, Liping
    Sheng, Zhixin
    HEMATOLOGICAL ONCOLOGY, 2012, 30 (04) : 163 - 169
  • [42] EXPERIENCE OF TREATMENT WITH LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (RVD) IN THE FIRST LINE IN PATIENTS DIAGNOSED WITH MULTIPLE MYELOMA IN THE HOSPITALS OF ARAGON AND THE PROVINCE OF SORIA
    Yus Cebrian, F.
    Paul Vidaller, P. J.
    Romero Quezada, L. L.
    Perella Arnal, M., I
    Campuzano Saavedra, V
    Sancho Val, L., I
    Gonzalez Gomez, N.
    Marco Amigot, J. J.
    Murillo Flores, I. M.
    Carrasco Baraja, V
    Godoy Molias, A. C.
    Paricio Moreno, M.
    Malo Yague, M.
    Delgado Beltran, M. P.
    Aguilar Franco, C.
    Palomera Bernal, L. R.
    HAEMATOLOGICA, 2017, 102 : 97 - 97
  • [43] Novel agents in first-line therapy for myeloma - From the multiple myeloma research foundation
    Jagannath, Sundar
    ONCOLOGY-NEW YORK, 2005, 19 (12): : 1551 - 1554
  • [44] A Real-World Comparison of First-Line Regimens in Transplant Ineligible Patients with Multiple Myeloma
    Abdallah, Nadine
    Chakraborty, Rajshekhar
    Visram, Alissa
    Gayowsky, Anastasia
    Pond, Gregory
    Seow, Hsien
    Kumar, Shaji
    Mian, Hira
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S217 - S218
  • [45] First-line therapy with bortezomib (formerly PS-341) in patients with multiple myeloma (MM).
    Jagannath, S
    Durie, B
    Wolf, J
    Camacho, E
    Irwin, D
    Lutzky, J
    McKinley, M
    Gabayan, E
    Crowley, J
    Schenkein, DP
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 570S - 570S
  • [46] How First-Line Therapy is Changing in non-Transplant Eligible Multiple Myeloma Patients
    Fazio, Francesca
    Deiana, Luca
    Loi, Cristian
    Mura, Francesca
    Petrucci, Maria Teresa
    Derudas, Daniele
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2025, 17 (01)
  • [47] Multi-omics analysis of multiple myeloma patients with differential response to first-line treatment
    Zheng, Bo
    Yi, Ke
    Zhang, Yajun
    Pang, Tongfang
    Zhou, Jieyi
    He, Jie
    Lan, Hongyan
    Xian, Hongming
    Li, Rong
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (07) : 3833 - 3846
  • [48] Multi-omics analysis of multiple myeloma patients with differential response to first-line treatment
    Bo Zheng
    Ke Yi
    Yajun Zhang
    Tongfang Pang
    Jieyi Zhou
    Jie He
    Hongyan Lan
    Hongming Xian
    Rong Li
    Clinical and Experimental Medicine, 2023, 23 : 3833 - 3846
  • [49] CLINICAL CHARACTERISTICS OF MULTIPLE MYELOMA PATIENTS DIAGNOSED BY NEPHROLOGIST
    Han, Byoung-Geun
    Kim, Jae Seok
    Kim, Young Sub
    Park, Hyun Cheol
    Song, Shin Han
    Choi, Seung Ok
    Shin, Seok Joon
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30
  • [50] Multiple Myeloma Velcade® in the First-Line: Flexibility in later Lines of Therapy
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (06) : 388 - 388
12345